We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-15.27%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$3.55B
AUM Growth
-$470M
Cap. Flow
+$314M
Cap. Flow %
8.85%
Top 10 Hldgs %
53.02%
Holding
59
New
5
Increased
5
Reduced
13
Closed
6

Top Buys

Rank Stock Value
1
EQRX
EQRx, Inc. Common Stock
EQRX
+$373M
2
GH icon
Guardant Health
GH
+$81.7M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$21.4M
4
SNCE
Science 37 Holdings, Inc. Common Stock
SNCE
+$20M
5
SEER icon
Seer Inc
SEER
+$18.7M

Top Sells

Rank Stock Value
1
DNA icon
Ginkgo Bioworks
DNA
+$34.1M
2
TWST icon
Twist Bioscience
TWST
+$33.9M
3
EXAS
Exact Sciences
EXAS
+$28.3M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$22.9M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$18.6M

Sector Composition

Rank Sector Weight
1 Healthcare 94.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STOK icon
51
Stoke Therapeutics
STOK
$1.84B
$2.88M 0.08%
120,000
– –
LIAN
52
DELISTED
LianBio American Depositary Shares
LIAN
$1.27M 0.04%
+206,415
New +$2.36M
SANA icon
53
Sana Biotechnology
SANA
$885M
$929K 0.03%
60,000
– –
FHTX icon
54
Foghorn Therapeutics
FHTX
$271M
– –
-215,000
Closed -$3M
NAUT icon
55
Nautilus Biotechnolgy
NAUT
$129M
– –
-225,000
Closed -$1.38M
SNDX icon
56
Syndax Pharmaceuticals
SNDX
$1.7B
– –
-1,200,000
Closed -$22.9M
TKNO icon
57
Alpha Teknova
TKNO
$284M
– –
-300,000
Closed -$7.47M
VRTX icon
58
CALL
Vertex Pharmaceuticals
VRTX
$119B
– –
-50,000
Closed -$9.07M
ORTX
59
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
– –
-257,500
Closed -$5.92M
1 2
3

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q4 2021 Portfolio in Review

As of Q4 2021, Casdin Capital held 59 positions worth $3.55B, down 12% from $4.02B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Casdin Capital deployed $314M of net new capital in Q4 2021, opening 5 new positions and adding to 5 existing holdings. Its largest new stake was EQRx, Inc. Common Stock: 39,527,669 shares worth $270M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 91% a quarter earlier.

On the sell side, the largest reduction was Ginkgo Bioworks, an estimated $34.1M trimmed.

  • Casdin Capital's largest Q4 2021 buy was EQRx, Inc. Common Stock: 39,527,669 shares worth $270M.
  • Casdin Capital added most to Sarepta Therapeutics in Q4 2021, an estimated $21.4M increase.
  • Casdin Capital's biggest Q4 2021 reduction was Ginkgo Bioworks, cutting an estimated $34.1M.
  • Casdin Capital fully exited Syndax Pharmaceuticals in Q4 2021, selling an estimated $22.9M.
  • Casdin Capital's ten largest holdings make up 53% of its $3.55B portfolio in Q4 2021.
  • Casdin Capital opened 5 new positions and closed 6 in Q4 2021.
  • Casdin Capital's portfolio value fell 12% quarter-over-quarter to $3.55B.

Based on Casdin Capital's 13F filing for Q4 2021, filed 14 Feb 2022.